Cipla Q3 Results Review - Inline Performance; Peptide Launches To Shape Near Term Growth: Systematix

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Systematix Research Report.Cipla Q3 FY24 earnings performance was in line with our estimates, but was ahead of consensus expectation on Ebitda. In the key markets - India and U.S., revenue growth was in line. India branded formulation delivered an 11% growth (including contribution from Galvus acquisition) and U.S. was flat QoQ. Cipla has guided for about five peptide approvals / launches coming through in FY25 which should help them build on the current base. We currently assume $30 million in incremental sales in the U.S. from these launches. With respect to the larger launches in the U.S., Cipla expects to complete the site transfer for gAdvair in mid-year FY25, while site transfer on gAbraxane will take longer. Hence these launches should get pushed into FY26 and the opportunity size may get diluted owing to competition. There is a possibility for gAbraxane approval to come sooner and ahead of site transfer completion if the Goa facility (currently under official action indicated) from where the product has been currently filed is inspected by the U.S. Food and Drug Food and Drug Administration and the site declared compliant. We are incrementally building $150 million contribution from limited competition launches in FY26 for Cipla which also includes contribution from gSymbicort that was successfully filed with the US FDA this quarter. We roll over our price target to FY26E earnings per share and recommend a hold at current market price. Our target price of Rs 1,349 is based on 21 times FY26E EPS. We expect high single digit revenue growth over FY23 – 26E and expect growth rates to decline thereafter led by erosion in gRevlimid..Click on the attachment to read the full report:.Cipla Q3 Results Review - Core Markets, Operating Leverage Drive Earnings Growth: Motilal Oswal.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Cipla Q3 Results Review - Inline Performance; Peptide Launches To Shape Near Term Growth: Systematix

Cipla has guided for about five peptide approvals / launches coming through in FY25 which should help them build on the current base.

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP